65,437 trials
Type 2 Diabetes
Primary: Hemoglobin A1c (HbA1c) Change From Baseline to Week 18 — 7.68; 7.69; 7.16; 7.07 Percent
Obesity
Primary: Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)…
Restless Legs Syndrome
Primary: Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension…
Opioid Dependency
Primary: The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in…
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
Diabetic Neuropathies
Primary: Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg) — -1.61; -2.47 units on a scale — p=<0.0001
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to Week 12 — -19.9; -20.8 mm Hg — p=0.395
HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Change From Baseline in Plasma HIV RNA (log10 Copies/mL) at Week 24 — -1.80; -1.87; -1.84; -0.35 HIV RNA (log10 copies/mL)
Sjogren's Syndrome
Primary: Change in Levels of Biomarkers After Dosing With Maxidex — -1.244; -0.29; -0.033; -0.33 ddCt (Delta-Delta-Ct)
Parkinson's Disease
Primary: Change in Early Morning UPDRS Part III Score — -7.0; -3.9 units on a scale — p=0.0002
Metabolic Syndrome
Primary: Beta Cell Function — 241.2; 232.3; 292.1; 287.6 microU/mM
Glaucoma, Open-angle · Ocular Hypertension
Primary: Mean Intraocular Pressure — 16.5 millimeters mercury (mm Hg)
HIV-1 Infection
Primary: Number of Participants Contributing to the Pharmacokinetic (PK) Evaluations: Cmin, Cmax, AUC24 & Css,av — 23; 21 participants
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Acne Vulgaris
Primary: Facial Irritation and Cutaneous Effects — 1.5; 5.4; 3.1; 7.8 Scores on a Scale